Namsco Corp Ordinary Shares NAMS 深 滬
已收盤 12-24 16:00:00 美东时间
35.65
-0.300
-0.83%
華盛通- 最 高36.16
- 今 開35.84
- 成交量 31.04万股
- 最 低 35.24
- 昨 收 35.95
- 總市值 40.28亿
- 52周最高 42.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 14.06
- 委 比 -97.31%
- 總股本 1.13亿
- 歷史最高 42.00
- 量 比 0.35
- 振 幅 2.56%
- 歷史最低 5.6326
- 每 手 1
- 風險率 6.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $44 to $50.
12-17 01:28
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral and raises the price target from $30 to $37.
12-03 02:14
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $44
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $39 to $44.
11-07 00:22
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
NewAmsterdam Pharma Q3 EPS $(0.61) Misses $(0.41) Estimate, Sales $348.000K Miss $5.287M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses of $(0.18) per share
11-05 21:07
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
New Amsterdam Pharma will present additional safety and efficacy data from its Phase 3 BROOKLYN, BROADWAY, and TANDEM trials at the 2025 American Heart Association Scientific Sessions in November. The company will also participate in three investor conferences, with live webcasts available on its investor relations website.
10-30 12:00
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
